Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome
Second Orphan Drug Designation for apraglutide, a next-generation, synthetic GLP-2 analog with a potentially best-in-class profile
BASEL, Switzerland, Jan. 16, 2019 -- (Healthcare Sales & Marketing Network) -- Therachon AG ("Therachon"), a cl... Biopharmaceuticals, Gastroenterology, FDA Therachon, apraglutide, short bowel syndrome, achondroplasia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news